XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments and Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

June 30,
2023 (Successor)
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$39.1 $26.5 $12.6 $— 
Equity securities
9.1 9.1 — — 
Interest rate cap23.8 — 23.8 — 
$72.0 $35.6 $36.4 $— 
Liabilities:
Deferred compensation liabilities$18.7 $— $18.7 $— 
Contingent consideration liabilities0.2 — — 0.2 

$18.9 $— $18.7 $0.2 
December 30,
2022 (Successor)
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts$36.6 $24.8 $11.8 $— 
Equity securities25.5 25.5 — — 
$62.1 $50.3 $11.8 $— 
Liabilities:
Deferred compensation liabilities$26.0 $— $26.0 $— 
Contingent consideration liabilities7.3 — — 7.3 
$33.3 $— $26.0 $7.3 
Schedule of Carrying Amount and Fair Value of Long-term Debt
The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:
Successor
June 30, 2023December 30, 2022
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
10.00% first lien senior secured notes due April 2025$480.0 $389.8 $475.9 $425.9 
10.00% second lien senior secured notes due April 2025257.6 60.3 242.2 216.8 
11.50% first lien senior secured notes due December 2028650.0 557.9 650.0 552.6 
10.00% second lien senior secured notes due June 2029184.1 52.7 175.5 176.7 
Level 2:
2017 Replacement Term loan due September 20271,220.8 1,026.2 1,222.1 1,037.8 
2018 Replacement Term loan due September 2027326.3 272.6 326.9 274.8 
Total Debt$3,118.8 $2,359.5 $3,092.6 $2,684.6 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:
SuccessorPredecessor
Three Months
Ended
June 30, 2023		Period from
June 17, 2022
through
July 1, 2022		Period from
April 2, 2022
through
June 16, 2022
FFF Enterprises, Inc.23.8 %23.6 %26.9 %
SuccessorPredecessor
Six Months
Ended
June 30, 2023		Period from
June 17, 2022
through
July 1, 2022		Period from
January 1, 2022
 through
June 16, 2022
FFF Enterprises, Inc.21.4 %23.6 %11.8 %
CuraScript, Inc.**15.6 
* Net sales to this distributor was less than 10.0% of the Company's total net sales for the respective periods presented above.

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
Successor
June 30,
2023		December 30,
2022
AmerisourceBergen Corporation
24.5 %23.3 %
McKesson Corporation
21.6 17.3 
FFF Enterprises, Inc.*16.2 
*Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above.
The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:
SuccessorPredecessor
Three Months
Ended
June 30, 2023		Period from
June 17, 2022
through
July 1, 2022		Period from
April 2, 2022
through
June 16, 2022
Acthar Gel24.6 %32.4 %24.6 %
INOmax16.2 15.8 17.4 
Therakos13.2 12.0 13.0 
APAP12.6 13.3 13.1 
SuccessorPredecessor
Six Months
Ended
June 30, 2023		Period from
June 17, 2022
through
July 1, 2022		Period from
January 1, 2022
 through
June 16, 2022
Acthar Gel22.1 %32.4 %25.4 %
INOmax17.7 15.8 19.0 
Therakos13.5 12.0 12.5 
APAP11.8 13.3 11.0